SFE · Safeguard Scientifics Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | - | - | - | - | - | - |
| SG&A | $5.68M | $4.78M | $7.15M | $9.47M | $9.98M | $16.87M |
| Total Operating Expenses | - | - | - | - | - | - |
| D&A | - | - | - | $0 | $692.0K | $322.0K |
| Operating Income | ($5.68M) | ($4.78M) | ($7.15M) | ($9.47M) | ($9.98M) | ($16.87M) |
| Interest Expense | - | - | - | $0 | $14.02M | $16.07M |
| Income Tax | $0 | $0 | - | $0 | $0 | $0 |
| Net Income | ($9.83M) | ($14.26M) | $27.00M | ($37.62M) | $54.56M | ($15.63M) |
| EPS - Basic | ($0.61) | ($0.87) | $1.36 | ($1.81) | $2.64 | ($0.76) |
| EPS - Diluted | ($0.61) | ($0.87) | $1.36 | ($1.81) | $2.64 | ($0.76) |
Balance Sheet
| Line item | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $9.50M | $13.33M | $24.74M | $15.60M | $25.03M | $7.70M |
| Accounts Receivable | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $107.0K | $16.0K | $41.0K | $56.0K | $39.0K | $165.0K |
| Current Assets | $9.91M | $21.42M | $30.28M | $16.06M | $26.35M | $48.83M |
| Total Assets | $22.84M | $37.69M | $54.03M | $69.03M | $107.58M | $145.74M |
| Current Liabilities | $2.05M | $1.82M | $1.73M | $3.47M | $2.43M | $32.94M |
| Long-term Debt | - | - | - | - | - | $68.60M |
| Total Liabilities | $2.86M | $3.12M | $3.46M | $6.16M | $5.84M | $78.76M |
| Stockholders' Equity | $19.98M | $34.58M | $50.57M | $62.88M | $101.74M | $66.98M |
| Retained Earnings | ($733.73M) | ($723.90M) | ($709.63M) | ($736.64M) | ($697.22M) | ($731.11M) |
Cash Flow
| Line item | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($3.31M) | ($3.26M) | ($8.15M) | ($8.14M) | ($19.97M) | ($26.04M) |
| Investing Cash Flow | $5.72M | ($4.66M) | $58.11M | ($1.27M) | $126.30M | $32.10M |
| Financing Cash Flow | ($6.25M) | ($3.49M) | ($40.80M) | ($40.0K) | ($89.48M) | ($24.95M) |
| CapEx | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - |
Ratios
| Metric | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | 0.0% | - |
| Return on assets | -43.0% | -37.8% | 50.0% | -54.5% | 50.7% | -10.7% |
| Return on equity | -49.2% | -41.3% | 53.4% | -59.8% | 53.6% | -23.3% |
| Return on invested capital | - | - | - | - | - | -9.8% |
| Liquidity | ||||||
| Current ratio | 4.84 | 11.79 | 17.46 | 4.63 | 10.85 | 1.48 |
| Quick ratio | 4.84 | 11.79 | 17.46 | 4.63 | 10.85 | 1.48 |
| Cash ratio | 4.64 | 7.34 | 14.27 | 4.50 | 10.30 | 0.23 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | 1.02 |
| Debt / Assets | - | - | - | - | - | 0.47 |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | -0.7x | -1.1x |
| Equity multiplier | 1.14 | 1.09 | 1.07 | 1.10 | 1.06 | 2.18 |
| Liabilities / Assets | 0.13 | 0.08 | 0.06 | 0.09 | 0.05 | 0.54 |
| Efficiency | ||||||
| Asset turnover | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | -19.0% | 33.2% | 24.4% | 5.2% | 40.8% | 1.5% |
| Net income growth (YoY) | 31.1% | - | - | - | - | 82.4% |
| EPS growth (YoY) | 29.9% | - | - | - | - | 82.5% |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | -42.2% | -31.6% | -19.6% | -38.2% | 51.9% | -18.1% |
Stability scores
Piotroski F-score
FY 2023 · 9-point quality
2/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✓No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Investors, NEC
Comparing SAFEGUARD SCIENTIFICS INC against the 5 most active filers in the same SIC group.